On December 15, 2024, Pharming Technologies B.V. (“Pharming”), a wholly-owned subsidiary of Pharming Group N.V., announced a recommended cash offer to the shareholders of Abliva AB (publ) (“Abliva”) to tender all their shares in Abliva to Pharming at a price of SEK 0.45 in cash per share (the “Offer”). An offer document relating to the Offer was published on January 15, 2025. On February 7, 2025, Pharming declared the Offer unconditional and announced that it would complete the Offer. Further, Pharming extended the acceptance period for the Offer until February 20, 2025.

At the end of the initial acceptance period of the Offer on February 7, 2025, the Offer had been accepted by shareholders representing a total of 1,413,841,472 shares, corresponding to approximately 87.71 percent of the total number of shares and votes in Abliva.¹

The number of shares tendered in the Offer during the extended acceptance period amounts to 47,327,703 shares, corresponding to approximately 2.94 percent of the total number of shares and votes in Abliva. In addition, Pharming has, since the announcement of the outcome of the Offer on February 7, 2025, acquired a total of 33,012,450 shares in Abliva outside the Offer, corresponding to approximately 2.05 percent of the total number of shares and votes in Abliva. No shares have been acquired at a price exceeding the price per share in the Offer.

As a result, Pharming controls in total 1,494,181,625 shares and votes in Abliva, corresponding to approximately 92.70 percent of the total number of shares and votes in Abliva.

^{1 Based on 1,611,884,536 issued shares in Abliva.}